CNS Orphan Diseases - The alternative route in CNS
Seminar - London, United Kingdom
A new study predicts that the overall market for medicines to treat and manage unusual Central Nervous System (CNS) disorders will expand from 2014 to 2024. The strength of this pharma segment stems from incentives in orphan drug development, including regulatory filing and first-mover advantages and protection. Also, despite small patient numbers, pharma companies can expect steady demand for a drug after approvals and commercial launches. Strong prospects exist.
SMi's masterclass hosted by QCTR will look at the challenges and potential advantages of developing drugs in CNS orphan diseases, compared to larger CNS indications and also looks at the support that is available to drug developers in orphan diseases. It will look at case studies of drug companies who have followed this route.
Key benefits to this masterclass are:
• This masterclass is essential attendance for anyone who wants to understand clinical trials in a rare CNS
disease
• Gain timely insight into key trial design strategies
• Discover the benefits of orphan disease regulations
• Learn from real-life case studies of how companies have approached these challenges
Organization: SMi Group
(Courtesy of central nervous system, via sharonostalecki.com)
Full more information, full programme details and to book online, please visit: www.smi-online.co.uk/2014orphan-cns2.asp
Tue, Apr 08, 2014 - Tue, Apr 08, 2014 (09:00 to 12:30)
Holiday Inn Bloomsbury
Coram Street, London, United Kingdom
If you'd like to ask a question or post a comment about this talk please do so below.
This seminar posting is brought to you by Biotechnology Calendar, Inc. providing access to research information and research tools for nearly 20 years. Visit our Science Market Update Blog for current science funding and market information or see our schedule of upcoming science research laboratory product shows.
